← Alle mensen

MO

Muhit Ozcan

3 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Re...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 december 2025

Pembrolizumab versus brentuximab vedotin bij recidief/refractair HL: KEYNOTE-204 fase III

The Lancet. Oncology · 2021-04

Polatuzumab vedotin bij recidief/refractair DLBCL: fase Ib/II

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 januari 2020